Misplaced Pages

This article needs additional citations for verification. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed. Find sources: "Epix Pharmaceuticals" – news · newspapers · books · scholar · JSTOR (June 2015) (Learn how and when to remove this message)

Epix Pharmaceuticals Inc. (formerly Predix Pharmaceuticals Inc.) was a pharmaceutical company based in Lexington, Massachusetts.

Its products included the following agents:

• PRX-00023—5-HT_1A receptor full agonist (later discovered to be an antagonist): for major depression and generalized anxiety disorder
• PRX-03140—5-HT₄ receptor partial agonist: for Alzheimer's disease
• PRX-07034—5-HT₆ receptor antagonist: for obesity and cognitive impairment associated with Alzheimer's disease and schizophrenia
• PRX-08066—5-HT_2B receptor antagonist: for pulmonary hypertension associated with chronic obstructive pulmonary disease

As of July 2009, the company was in the process of asset liquidation due to insufficient funds to stay afloat.

References

1. Weisman, Robert (22 July 2009). "Epix Pharmaceuticals of Lexington is latest biotech to fall to funding crunch". The Boston Globe. Retrieved 23 November 2011.

External links

• EPIX Pharmaceuticals, Inc. web site

This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Misplaced Pages by expanding it.

• v
• t
• e

• Defunct pharmaceutical companies of the United States
• Companies based in Lexington, Massachusetts
• Health care companies based in Massachusetts
• Defunct companies based in Massachusetts
• Companies formerly listed on the Nasdaq
• Pharmaceutical companies disestablished in 2009
• Medical company stubs